Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

Next Previous
X
Search
Trial Profile

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms DORA

    • Most Recent Events

    • 18 Jan 2024 Results assessing safety and efficacy of of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer published in the Clinical Cancer Research
    • 10 Dec 2022 Primary endpoint (Efficacy of Olaparib in Combination With Durvalumab as Assessed by PFS (Progression-free Survival)) has been met, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium.
    • 10 Dec 2022 Primary endpoint (Efficacy of Olaparib Alone as Assessed by PFS (Progression-free Survival) Reported as Events Per Month) has been met, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top